Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.

Abstract: The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid.

Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.

Abstract: Compositions and methods comprising or using a combination of an adjuvant such as AS01B and an antigen such as a ?-amyloid antigen are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's disease. Suitable ?-amyloid antigens are A?1-5, A?1-6, A?1-7, A?1-10, A?1-14, A?1-15, A?2-7, A?2-8, A?3-7, A?3-8, A?11-16, A?11-17, A?p(E)3-7, A?p(E)3-8, A?p(E)3-40, A?p(E)3-42, A?p(E)11-16, A?p(E)11-17, A?p(E)11-40 or A?p(E)11-42, optionally with a protein carrier. Suitable adjuvants comprise QS21, 3D-MPL or an AGP, optionally in combination with a liposome.